Despite extensive efforts, and new technologies for determining effective neutralising antibody targets 1 , a vaccine that is effective in protecting against acquisition of HIV has not been developed and is unlikely in the short to medium term. HIV 'cure' research is still in its infancy and considerable progress needs to be achieved in order to understand the immunological requirements to achieve a functional ). While it is important to carefully age-match the cohorts given that age is a major factor determining the level of chronic inflammation/immune activation Large-scale prospective and retrospective longitudinal studies are required to both determine whether effective virologic suppression eventually decreases inflammation to age-adjusted, healthy levels and to determine how HIV-related inflammation contributes to elevated risk of inflammatory co-morbidities. These studies will inform the need for adjunctive therapies to reduce inflammationrelated comorbidities in HIV+ patients receiving antiretroviral therapy.
